A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 9262 participants.
Also called NCT07551492
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 9,262 participants
- Registry
-
NCT07551492
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07551492. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2031-05-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- HRS9531
- Intervention (Drug)
- HRS9531 placebo
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07551492- Content hash
9117a510513436e4dcf762b52df2531e6fe180e679c9d530eaa4bac9fab4422a